(Ceftibuten + ledaborbactam etzadroxil) is under clinical development by VenatoRx Pharmaceuticals and currently in Phase I for Enterobacteriaceae Infections. According to GlobalData, Phase I drugs for Enterobacteriaceae Infections have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Ceftibuten + ledaborbactam etzadroxil)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Ceftibuten + ledaborbactam etzadroxil) overview
Fixed dose combination of ceftibuten and ledaborbactam etzadroxil is under development for the treatment of extended spectrum beta-lactamase bacetrial infections (EBL), cUTI, including acute pyelonephritis and carbapenem-resistant Enterobacteriaceae (CRE) infections. It is administered by oral route. The drug candidate is a small molecule, next generation beta-lactamase inhibiting antibiotic and acts by targeting beta lactamase.
VenatoRx Pharmaceuticals overview
VenatoRx Pharmaceuticals (VenatoRx) discovers and develops novel anti-infectives for the treatment of multi-drug resistant (MDR) bacterial infections and viral infections. The company’s pipeline portfolio includes taniborbactam, an injectable beta-lactamase inhibitor (BLI), against all the major sub-classes of beta-lactamases; VNRX-7145, an orally bioavailable BLI against both extended-spectrum beta-lactamases (ESBLs) and carbapenem-resistant Enterobacteriaceae. It is also investigating penicillin-binding proteins (PBP) inhibitor programs for the treatment of Neisseria gonorrhoeae and VNRX-9945 for testing HBV-infected patients and other novel anti-bacterial and anti-viral programs. VenatoRx is headquartered in Malvern, Pennsylvania, the US.
For a complete picture of (Ceftibuten + ledaborbactam etzadroxil)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
